RIGL
Rigel Pharmaceuticals, Inc. NASDAQ Listed Nov 29, 2000$26.28
Mkt Cap $486.2M
52w Low $16.88
26.6% of range
52w High $52.24
50d MA $29.17
200d MA $34.29
P/E (TTM)
1.4x
EV/EBITDA
6.1x
P/B
1.4x
Debt/Equity
0.1x
ROE
93.8%
P/FCF
10.2x
RSI (14)
—
ATR (14)
—
Beta
1.27
50d MA
$29.17
200d MA
$34.29
Avg Volume
349.2K
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
1180 Veterans Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.80 | 0.47 | -40.9% | 28.09 | +2.2% | -5.1% | -1.6% | -0.8% | — | — | — |
| Mar 3, 2026 | AMC | 1.33 | 1.14 | -14.3% | 33.02 | -8.3% | -10.3% | -0.4% | -2.2% | -2.8% | +1.3% | — |
| Nov 4, 2025 | AMC | 0.93 | 1.46 | +57.0% | 28.38 | +22.9% | +33.4% | -4.6% | -2.6% | -1.8% | +9.8% | — |
| Aug 5, 2025 | AMC | 1.97 | 3.28 | +66.5% | 24.24 | +12.1% | +23.0% | +2.1% | +4.1% | +5.6% | +3.2% | — |
| May 6, 2025 | AMC | 0.14 | 0.63 | +350.0% | 18.26 | +23.5% | +1.2% | +2.3% | -0.7% | -0.9% | -1.7% | — |
| Mar 4, 2025 | AMC | 0.30 | 0.80 | +166.7% | 22.08 | -8.7% | -8.1% | -2.9% | +4.2% | -4.8% | -0.2% | — |
| Nov 7, 2024 | AMC | 0.06 | 0.70 | +1066.7% | 15.44 | +7.8% | +42.9% | +13.0% | +9.1% | +0.7% | +0.2% | — |
| Aug 6, 2024 | AMC | -0.37 | -0.06 | +83.8% | 9.33 | +12.5% | +5.8% | +5.7% | -2.1% | +10.2% | +12.6% | — |
| May 7, 2024 | AMC | -0.30 | -0.50 | -66.7% | 11.90 | -6.7% | -16.6% | +2.8% | -3.5% | -0.2% | -3.5% | — |
| Mar 5, 2024 | AMC | 0.02 | 0.04 | +99.9% | 14.80 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% | — |
| Nov 7, 2023 | AMC | -0.70 | -0.30 | +57.1% | 8.71 | +3.3% | +2.2% | -8.2% | +0.1% | -2.1% | +6.1% | — |
| Aug 1, 2023 | AMC | -0.80 | -0.40 | +50.0% | 13.30 | +1.5% | -3.0% | -2.3% | -3.2% | -2.5% | -1.7% | — |
| May 2, 2023 | AMC | -0.90 | -0.80 | +11.1% | 11.40 | -1.8% | +0.9% | +1.7% | +0.9% | +0.8% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 5 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $28.38 | $34.87 | +22.9% | +33.4% | -4.6% | -2.6% | -1.8% | +9.8% |
| Nov 5 | Jefferies | Upgrade | Hold → Buy | — | $28.38 | $34.87 | +22.9% | +33.4% | -4.6% | -2.6% | -1.8% | +9.8% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.50 | $30.25 | +2.5% | -2.5% | -1.3% | -0.8% | -4.8% | +2.0% |
| Aug 6 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $24.24 | $27.18 | +12.1% | +23.0% | +2.1% | +4.1% | +5.6% | +3.2% |
| May 7 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $18.26 | $22.55 | +23.5% | +1.2% | +2.3% | -0.7% | -0.9% | -1.7% |
| Mar 6 | Citigroup | Maintains | Buy → Buy | — | $20.29 | $20.28 | -0.0% | -2.9% | +4.2% | -4.8% | -0.2% | +4.8% |
| Mar 5 | B. Riley Securities | Maintains | Neutral → Neutral | — | $22.08 | $20.15 | -8.7% | -8.1% | -2.9% | +4.2% | -4.8% | -0.2% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.08 | $20.15 | -8.7% | -8.1% | -2.9% | +4.2% | -4.8% | -0.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.81 | $21.57 | -1.1% | +1.5% | +0.1% | -2.0% | +2.0% | +1.5% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.81 | $22.02 | +1.0% | +0.0% | +1.5% | +0.1% | -2.0% | +2.0% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.11 | $17.22 | +0.6% | -2.5% | +7.9% | -3.7% | +16.0% | +8.3% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.16 | $22.37 | -3.4% | -11.2% | -5.0% | -2.7% | -0.5% | +1.2% |
| Dec 10 | B. Riley Securities | Maintains | Neutral → Neutral | — | $23.16 | $22.37 | -3.4% | -11.2% | -5.0% | -2.7% | -0.5% | +1.2% |
| Dec 10 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $23.16 | $22.37 | -3.4% | -11.2% | -5.0% | -2.7% | -0.5% | +1.2% |
| Dec 6 | B. Riley Securities | Maintains | Neutral → Neutral | — | $26.03 | $26.22 | +0.7% | -2.2% | -9.0% | -11.2% | -5.0% | -2.7% |
| Nov 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $27.41 | $27.80 | +1.4% | +0.2% | -12.2% | -5.6% | +5.1% | +1.7% |
| Nov 12 | Citigroup | Maintains | Buy → Buy | — | $24.95 | $25.00 | +0.2% | +9.1% | +0.7% | +0.2% | -12.2% | -5.6% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.43 | $14.43 | +0.0% | -1.9% | +2.5% | -1.2% | -0.5% | -4.5% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.43 | $10.50 | +0.7% | -2.1% | +10.2% | +12.6% | -5.5% | +4.2% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.00 | -5.9% | -11.8% | -6.3% | +20.6% | -13.7% | +2.3% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.53 | $9.50 | -0.3% | -2.8% | -2.5% | +5.8% | -0.5% | +0.6% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.78 | $10.00 | +2.2% | +0.5% | -0.8% | +0.2% | -1.7% | -1.0% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.90 | $11.10 | -6.7% | -16.6% | +2.8% | -3.5% | -0.2% | -3.5% |
| Mar 7 | Citigroup | Maintains | Buy → Buy | — | $15.60 | $15.90 | +1.9% | -1.9% | +2.6% | -3.8% | -1.3% | -2.7% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.80 | $15.40 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% |
| Mar 6 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $14.80 | $15.40 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% |
| Mar 6 | B. Riley Securities | Maintains | Neutral → Neutral | — | $14.80 | $15.40 | +4.1% | +5.4% | -1.9% | +2.6% | -3.8% | -1.3% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.20 | $12.10 | +8.0% | +16.1% | +1.5% | +7.6% | +5.6% | +3.3% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.50 | $14.90 | +2.8% | +2.8% | -7.4% | +7.2% | -7.4% | -0.7% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.40 | $11.70 | +2.6% | +16.2% | -3.4% | -2.3% | +4.0% | -1.5% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.30 | $13.50 | +1.5% | -3.0% | -2.3% | -3.2% | -2.5% | -1.7% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.40 | $11.20 | -1.8% | +0.9% | +1.7% | +0.9% | +0.8% | -2.5% |
| Mar 9 | Citigroup | Maintains | Buy → Buy | — | $17.90 | $18.00 | +0.6% | -6.1% | -5.7% | -0.3% | +1.9% | +4.3% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.70 | $18.10 | +23.1% | +21.8% | -6.1% | -5.7% | -0.3% | +1.9% |
| Dec 2 | Citigroup | Upgrade | Neutral → Buy | — | $6.84 | $9.39 | +37.3% | +21.9% | +13.9% | -2.9% | -2.9% | +0.2% |
| Nov 4 | BMO Capital | Maintains | Outperform → Outperform | — | $7.26 | $7.53 | +3.7% | +1.9% | +0.8% | -2.1% | -8.2% | +7.3% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.90 | $17.30 | +8.8% | +1.9% | -6.2% | -2.0% | +15.4% | -4.1% |
| Aug 17 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.60 | $15.40 | -1.3% | +1.9% | +1.9% | -6.2% | -2.0% | +15.4% |
| Jun 9 | B. Riley Securities | Maintains | Neutral → Neutral | — | $7.01 | $7.37 | +5.1% | +2.4% | -6.3% | +3.0% | +5.8% | +11.2% |
| Jun 9 | BMO Capital | Maintains | Outperform → Outperform | — | $7.01 | $7.37 | +5.1% | +2.4% | -6.3% | +3.0% | +5.8% | +11.2% |
| Jun 9 | Citigroup | Downgrade | Buy → Neutral | — | $7.01 | $7.37 | +5.1% | +2.4% | -6.3% | +3.0% | +5.8% | +11.2% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.60 | $8.88 | -49.5% | -60.2% | +2.4% | -6.3% | +3.0% | +5.8% |
| Jun 8 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $17.60 | $8.88 | -49.5% | -60.2% | +2.4% | -6.3% | +3.0% | +5.8% |
| Mar 23 | B. Riley Securities | Maintains | Neutral → Neutral | — | $33.40 | $32.90 | -1.5% | -7.5% | +6.1% | -3.0% | -1.6% | +0.0% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.30 | $53.20 | +17.4% | +5.1% | -2.1% | -1.1% | -11.5% | +7.1% |
| Nov 9 | JP Morgan | Downgrade | Overweight → Neutral | — | $26.20 | $24.90 | -5.0% | -0.4% | +5.0% | +0.7% | -3.3% | +3.0% |
| Aug 6 | Citigroup | Maintains | Buy → Buy | — | $25.20 | $25.00 | -0.8% | -2.4% | +4.9% | +0.8% | -2.3% | -1.6% |
| May 27 | JP Morgan | Maintains | Overweight → Overweight | — | $19.80 | $19.90 | +0.5% | +3.0% | -0.5% | -3.7% | -1.3% | +2.1% |
| Dec 9 | BMO Capital | Maintains | Outperform → Outperform | — | $21.70 | $21.20 | -2.3% | -0.5% | +3.9% | +1.6% | -0.9% | -1.3% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.90 | $23.20 | +1.3% | +2.2% | -3.8% | +0.9% | +3.5% | -4.7% |
No insider trades available.
8-K · 1.02
!! High
Rigel Pharmaceuticals Inc. (New) -- 8-K 1.02: Material Agreement Terminated
Rigel Pharmaceuticals terminated its CNS disease program effective June 15, 2026, eliminating a potential revenue stream and narrowing its pipeline focus to other therapeutic areas.
Apr 21
8-K
Rigel Pharmaceuticals Inc. (New) -- 8-K Filing
Rigel Pharmaceuticals reported Q4 2025 revenue from three marketed drugs—TAVALISSE, GAVRETO, and REZLIDHIA—demonstrating progress in its hematologic disorders and cancer portfolio.
Mar 3
8-K · 5.02
!!! Very High
Rigel Pharmaceuticals Inc. (New) -- 8-K 5.02: Executive Change
Rigel Pharmaceuticals appointed Michael P. Miller as a director, potentially strengthening its board governance and oversight capabilities.
Feb 3
Data updated apr 26, 2026 10:48pm
· Source: massive.com